Search
Metipranolol
go.drugbank.com/drugs/DB01214ApprovedWithdrawnA beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.
Muraglitazar
go.drugbank.com/drugs/DB06510InvestigationalIt belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. … In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease
Cedirogant
go.drugbank.com/drugs/DB18951InvestigationalCedirogant is under investigation in clinical trial NCT05044234 (A Study to Assess Adverse Events and Disease Activity With Cedirogant (ABBV-157) in Adult Participants With Moderate to Severe Psoriasis
Nordazepam
go.drugbank.com/drugs/DB14028InvestigationalAn intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.
Zilebesiran
go.drugbank.com/drugs/DB18929InvestigationalZilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care
Atuliflapon
go.drugbank.com/drugs/DB19029InvestigationalAtuliflapon is under investigation in clinical trial NCT05251259 (Study to Assess the Efficacy and Safety of Atuliflapon in Moderate-to-severe Uncontrolled Asthma).
AM336
go.drugbank.com/drugs/DB06563ExperimentalLeconotide (development codes CNSB004 and AM336) is an omega-conotoxin peptide known for its analgesic properties, which work by blocking neuronal voltage-sensitive calcium channels.
Tanespimycin
go.drugbank.com/drugs/DB05134InvestigationalTanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90).
Affitope AD01
go.drugbank.com/drugs/DB06086InvestigationalAffitope AD01 is an investigational drug developed for immunization to treat Alzheimer's Disease.
ETC-1001
go.drugbank.com/drugs/DB05866ExperimentalETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.